C. Shovlin, A. Guttmacher, and E. Buscarini, Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome), American Journal of Medical Genetics, vol.32, issue.1, pp.66-73, 2000.
DOI : 10.1002/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P

T. Haitjema, W. Balder, F. Disch, and C. Westermann, Epistaxis in hereditary haemorrhagic telangiectasia, Rhinology, vol.34, pp.176-184, 1996.

I. Karapantzos, N. Tsimpiris, D. Goulis, H. Van-hoecke, P. Van-cauwenberge et al., Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire, European Archives of Oto-Rhino-Laryngology, vol.111, issue.10, pp.830-833, 2005.
DOI : 10.1007/s00405-004-0911-0

B. Folz, T. J. Lippert, B. Werner, and J. , Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease, Rhinology, vol.43, pp.40-46, 2005.

K. Mcallister, K. Grogg, and D. Johnson, Endoglin, a TGF-?? binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1, Nature Genetics, vol.23, issue.4, pp.345-51, 1994.
DOI : 10.1006/geno.1994.1134

D. Johnson, J. Berg, and M. Baldwin, Mutations in the activin receptor???like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2, Nature Genetics, vol.370, issue.2, pp.189-95, 1996.
DOI : 10.1038/ng0696-189

C. Gallione, G. Repetto, and E. Legius, A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4), The Lancet, vol.363, issue.9412, pp.852-861, 2004.
DOI : 10.1016/S0140-6736(04)15732-2

L. David, C. Mallet, S. Mazerbourg, J. Feige, and S. Bailly, Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells, Blood, vol.109, issue.5, pp.1953-61, 2007.
DOI : 10.1182/blood-2006-07-034124
URL : https://hal.archives-ouvertes.fr/inserm-00376097

S. Dupuis-girod, I. Ginon, and J. Saurin, Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output Ex vivo study of bevacizumab transport through porcine nasal mucosa. European journal of pharmaceutics and biopharmaceutics The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia, JAMA : the journal of the American Medical Association eV Laryngoscope, vol.30780119, issue.11, pp.948-55465, 2009.

C. Rohrmeier, H. Sachs, and T. Kuehnel, A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia, European Archives of Oto-Rhino-Laryngology, vol.120, issue.2, pp.531-537, 2012.
DOI : 10.1007/s00405-011-1721-9

T. Davidson, S. Olitsky, J. Wei, T. Karnezis, T. Davidson et al., Hereditary hemorrhagic telangiectasia Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis Safety of intranasal Bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee, Clinical cancer research : an official journal of the American Association, pp.432-437, 2010.

D. Ternant, N. Ceze, and T. Lecomte, An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer Bevacizumab-induced nasal septum perforation, Ther Drug Monit Expert Opin Drug Saf Oncologist Oncologist, vol.3251111, issue.20, pp.647-52553, 2006.

N. Ruiz, C. Fernandez-martos, and I. Romero, Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer Karnezis TT, Davidson TM. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy, J Clin Oncol Laryngoscope, vol.25122, issue.23, pp.3376-7495, 2007.

S. Kaja, J. Hilgenberg, E. Everett, S. Olitsky, J. Gossage et al., Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies, Human antibodies, vol.20, pp.95-101, 2011.

R. Guldmann, A. Dupret, Y. Nivoix, P. Schultz, and C. Debry, Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with rendu-osler disease, The Laryngoscope, vol.119, issue.5, pp.953-958, 2012.
DOI : 10.1002/lary.23230